Hepatitis News
August 2006
'KC Star' Investigation Leads to $1 Billion Hepititis C Settlement
“Evidence uncovered by The Kansas City Star helped bring about a $1 billion
settlement for approximately 5,500 Canadians with Hepatitis C, the paper reported
today.”
New
hope for Hepatitis C research
“The mystery surrounding Hepatitis C, a disease that affects millions
of people worldwide, is one step closer to being solved.”
MedMira
Offers New Rapid Diagnostic to Combat "the hidden epidemic -Co-infection
with HIV/Hepatitis C
“Multiplo Delivers Simultaneous Rapid Diagnosis of HIV and Hepatitis C - XVI
International AIDS Conference”
An estimated 56,000 Canadians are living
with HIV infection (The Public Health Agency of Canada)
Hepatitis C-related liver cancer mortality on the rise: report
“The mortality rate of hepatitis C-related liver cancer has been rising
in Taiwan, particularly in the southern counties of Yunlin, Jiayi and Tainan,
according to a study report released Saturday.”
African American
patients with hepatitis C (HCV) infections experience a lower response rate
to the peginterferon alfa-2a and ribavirin combination treatment than Caucasian
Americans...
“Racial differences in viral responses were seen as
early as the fourth week of treatment.”
Hep C activist dies at 48
“Neil Van Dusen, an outspoken victim of Canada's tainted
blood scandal, died Monday of complications from hepatitis C. He
was 48.”
Phynova
Group Plc (“phynova” and or the “company”)
Granted First UK Patent for PYN17 A Botanical Drug for the Treatment of Hepatitis
C
“Phynova Group plc, a developer of Western pharmaceuticals based on safe
and effective Chinese medicines, is pleased to announce that the UK Patent
Office has granted a key patent to cover and protect its Hepatitis C treatment
programmes.”
HIV/HCV coinfected patients more prone to end-stage liver disease
without treatment
“Individuals coinfected with HIV and hepatitis C virus are more likely
to develop end-stage liver disease (ESLD) compared to patients with hepatitis
C virus, alone, according to a study presented at the Sixteenth International
AIDS Conference in Toronto on August 15th.”
Media Statement on NICE Guidance for Treatment of Mild Hepatitis C
“The Hepatitis C Trust is delighted with the NICE guidance issued today
as it gives patients the opportunity to be treated during the early stages
of hepatitis C, before measurable damage occurs to their liver. This guidance
offers a lifeline to hundreds of thousands of people in the UK who now have
the hope of an early cure.”
'Many people with hepatitis C feel very dirty'
“A Huddersfield woman has spoken of the misery of an illness which has
left her wanting to take her own life. Netherton woman Maureen Ross,
55, has suffered from the hepatitis C virus for 13 years, leaving her so lethargic
that she feels suicidal.”
UK's NICE backs Roche, Schering-Plough hep C drugs
“Two similar drug treatments for hepatitis C from Roche and Schering-Plough
have been recommended for use on Britain's state-run health service.”
Inovio Reveals Positive Data From The Combined ChronVac-C DNA Vaccine
And Inovio's MedPulser DNA Delivery System - Update
“Inovio Biomedical Corp. a bio-medical company said its partner, Tripep
AB of Sweden has achieved additional positive pre-clinical results from the
combination of ChronVac-C DNA vaccine and Inovio's MedPulser DNA delivery system.”
Japan court awards damages over hepatitis C infections
“A court has ordered the Japanese government and drugmakers to pay 168
million yen (1.4 million dollars) to 11 people who contracted hepatitis C from
tainted blood products.”
Clinical Trials, Cohort Studies, and Pilot Studies
Peginterferon-alfa2a
plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis
C virus RNA at week 4 of treatment.
Sanchez-Tapias
JM, et al. Gastroenterology. 2006
Aug;131(2):451-60.
Hepatitis
C virus genotypes and viral concentrations in participants of a general population
survey in the United States.
Nainan
OV, et al. Gastroenterology. 2006
Aug;131(2):478-84.
Peginterferon
and ribavirin treatment in African American and Caucasian American patients
with hepatitis C genotype 1.
Conjeevaram
HS, et al. Gastroenterology. 2006
Aug;131(2):470-7.
The
results of a randomized trial looking at 24 weeks vs 48 weeks of treatment
with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients
with chronic hepatitis C genotype 1.
Brandao
C, et al. J
Viral Hepat. 2006 Aug;13(8):552-9.
Effectiveness
of interferon plus ribavirin combination in the treatment of naive patients
with hepatitis C virus type 5. A French multicentre retrospective study. Bonny
C, et al. Aliment
Pharmacol Ther. 2006 Aug 15;24(4):593-600.
Long-term
follow-up of previous hepatitis C virus positive nonresponders to interferon
monotherapy successfully retreated with combination therapy: are they really
cured? Ciancio
A, et al. Am
J Gastroenterol. 2006 Aug;101(8):1811-6. Epub 2006 Jun 16.
A
randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral
effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with
chronic hepatitis C (COMPARE). Silva
M, et al. J
Hepatol. 2006 Aug;45(2):204-13. Epub 2006 Apr 18.
Mental and physical
symptoms associated with lower social support for patients with hepatitis
C.
Blasiole
JA, et al. World
J Gastroenterol. 2006 Aug 7;12(29):4665-72
Influence
of interferon therapy on outcome after surgery for hepatitis C virus-related
hepatocellular carcinoma.
Uenishi
T, et al. Hepatol
Res. 2006 Aug 23; [Epub ahead of print]
A
Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients
with Chronic Hepatitis C.
Ngo
Y, et. al. Clin
Chem. 2006 Aug 24; [Epub ahead of print]
Outcomes and Treatment of Acute Hepatitis C Virus Infection
in a United States Population.
Corey
KE, et al. Clin
Gastroenterol Hepatol. 2006 Aug 21; [Epub ahead of print]
Evolution
of Hepatitis C Virus Quasispecies during Ribavirin and Interferon-Alpha-2b
Combination Therapy and Interferon-Alpha-2b Monotherapy.
Arataki
K, et al. Intervirology. 2006
Aug 21;49(6):352-361 [Epub ahead of print]
Cancer incidence in
people with hepatitis B or C infection: a large community-based linkage study.
Amin
J, et al. J
Hepatol. 2006 Aug;45(2):197-203. Epub 2006 Mar 31.
Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean
cohort: 20 years of follow-up.
Ribes
J, et al. Int
J Cancer. 2006 Aug 1;119(3):687-94.
Prolonged
Negative HCV-RNA Status Led to a Good Outcome in Chronic Hepatitis C Patients
with Genotype 1b and Super-High Viral Load.
Kohno
H, et al. Intervirology. 2006
Aug 21;49(6):362-369 [Epub ahead of print]
The
contributions of hepatitis B virus and hepatitis C virus infections to
cirrhosis and primary liver cancer worldwide.
Perz
JF, et al. . J
Hepatol. 2006 Oct;45(4):529-38. Epub 2006 Jun 23.
More advanced hepatic fibrosis in hispanics with chronic
hepatitis C infection: role of patient demographics, hepatic necroinflammation,
and steatosis. Verma
S, et al. Am
J Gastroenterol. 2006 Aug;101(8):1817-23. Epub 2006 Jun 22.
Basic and Applied Science, Pre-Clinical Studies
Variations
in the Viral NS5B Region in Japanese Patients with Chronic Hepatitis C Virus
Genotype 1b Infection. Sugihara
K, et al. Intervirology. 2006
Aug 21;49(6):319-326 [Epub ahead of print]
CR5Delta32
mutation does not influence the susceptibility to HCV infection, severity
of liver disease and response to therapy in patients with chronic hepatitis
C. Goyal
A, et al. World
J Gastroenterol. 2006 Aug 7;12(29):4721-6
HepG2
cells support viral replication and gene expression of hepatitis C virus
genotype 4 in vitro.
El-Awady
MK, et. al. World
J Gastroenterol. 2006 Aug 14;12(30):4836-42.
Association
of genetic polymorphism of low-density lipoprotein receptor with chronic
viral hepatitis C infection in Han Chinese.
Li
H, Liu
Z, Han
Q, Li
Y, Chen
J. J
Med Virol. 2006 Oct;78(10):1289-95.
Altered expression and activation
of signal transducers and activators of transcription (STATs) in
hepatitis C virus infection: in vivo and in vitro studies. Larrea
E, et al. Gut. 2006
Aug;55(8):1188-96. Epub 2005 Aug 24.
Dynamics
of interferon-specific gene expression in peripheral blood of interferon
alfa-naive patients with genotype 1 chronic hepatitis C infection treated
with albumin-interferon alfa. Bain
VG, et al. Hepatol
Res. 2006 Aug;35(4):256-62. Epub 2006 May 30.
Non-nucleoside
inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism
of inhibition.
Biswal, BK, et al. J
Mol Biol. 2006 Aug 4;361(1):33-45. Epub 2006 Jun 16.
Viral and Cellular Determinants of Hepatitis C Virus
Envelope-Heparan Sulfate Interaction.
Barth
H, J Virol. 2006
Aug 23; [Epub ahead of print]
HIV/HCV Coinfection
Rates
and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects.
Butt
AA, et al. Aliment
Pharmacol Ther. 2006 Aug 15;24(4):585-91.
Cost-effectiveness
of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and
hepatitis C virus co-infection.
Hornberger
J, et al. J
Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9.
Complete genomic sequences for hepatitis C virus subtypes 6e and 6g
isolated from Chinese patients with injection drug use and HIV-1 co-infection.
Li
C, et al. J
Med Virol. 2006 Aug;78(8):1061-9.
Hepatic
steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis
C virus genotype 3 infection in HIV-seropositive patients.
McGovern
BH, et al. Clin
Infect Dis. 2006 Aug 1;43(3):365-72. Epub 2006 Jun 22.
HIV
Coinfection Impairs CD28-Mediated Costimulation of Hepatitis C Virus-Specific
CD8 Cells.
Yonkers
NL, et al. J
Infect Dis. 2006 Aug 1;194(3):391-400. Epub 2006 Jun 30.
Increase in HCV incidence in HIV-1 infected patients followed since
primary infection.
Ghosn
J, et al. Sex
Transm Infect. 2006 Aug 21; [Epub ahead of print]
Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion
after pegylated interferon-alpha2b plus ribavirin treatment in a patient
with hepatitis B and C coinfection. Rautou
PE, et al.
Complementary and Alternative Therapies
The
effect of antioxidant supplementation on hepatitis C viral load, transaminases
and oxidative status: a randomized trial among chronic hepatitis C virus-infected
patients. Groenbaek
K, et al. Eur
J Gastroenterol Hepatol. 2006 Sep;18(9):985-989.
MISCELLANEOUS
Hepatitis
C - contamination of toothbrushes: myth or reality? Lock
G, et al. J
Viral Hepat. 2006 Sep;13(9):571-3.
Face-to-face
interviewing in predonation screening: lack of effect on detected human immunodeficiency
virus and hepatitis C virus infections.
O'brien
SF, et al. Transfusion. 2006
Aug;46(8):1380-7.
From
Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-alpha-2b/Ribavirin
Combination Therapy for Naive Chronic Hepatitis C Patients. Piai
G, et al. Dig
Dis Sci. 2006 Aug 22; [Epub ahead of print]
Hepatitis
C, metabolic syndrome, and inflammatory markers: Results from the Third National
Health and Nutrition Examination Survey [NHANES III]. Shaheen
M, et al. Diabetes
Res Clin Pract. 2006 Aug 16; [Epub ahead of print]
Case
finding for hepatitis C in primary care: a cost utility analysis. Thompson
Coon J, Fam
Pract. 2006 Aug;23(4):393-406. Epub 2006 Jun 23.
|
